SUN-541 Effect of Testosterone Replacement Therapy Added to Intensive Lifestyle Intervention in Frail, Older Male Veterans with Hypogonadism and Obesity: A Randomized Clinical Trial
Authors: Barnouin Yoann , Celli Alessandra , Jiang Bryan , Paudyal Arjun , Nambi Vijay , Monthaporn Bryant , Villareal Reina Condevillamar , Marcelli Marco , Garcia Jose Manuel , Qualls Clifford , Villareal Dennis Tan 
Published: May 2020

Abstract
Background
Both hypogonadism and obesity are common in older men which additively exacerbate their age-related decline in physical function resulting in frailty. However, the appropriate treatment approach for frail, older men with hypogonadism and obesity is still controversial.
Methods
In this randomized, comparative efficacy, double-blinded, placebo-controlled (for testosterone) trial, we examined the effect of 6-months: 1) lifestyle therapy (diet-induced weight loss and supervised aerobic and resistance exercise training) + testosterone replacement therapy (LT+Test) vs. 2) lifestyle therapy + placebo (LT+Pbo) in 83 older (age≥65 years) male veterans with obesity (BMI≥30 kg/m2) and evidence of persistently low AM serum testosterone (&lt;300 ng/dl) associated with physical frailty. The primary outcome was change in score in the modified Physical Performance Test (PPT). Secondary outcomes included other frailty measures, body composition, bone mineral density, and physical functions.
Results
In the intention-to-treat analysis, the score in the PPT increased similarly in the LT+Test group and LT+Pbo (increase from baseline of 17% vs. 17%, respectively; P=0.78 for between-group comparison). Peak oxygen consumption (VO2peak) increased more in the LT+Test group than in the LT+Pbo group (increase of 23% vs. 16%, respectively; P=0.04). Moreover, despite equivalent weight loss between groups (both groups lost 9% of body weight from baseline), lean body mass decreased less in the LT+Test group than in LT+Pbo group (-1.8% vs. -3.5%, respectively; P=0.02). Likewise, bone mineral density at the total hip was relatively preserved in the LT+Test group compared to the LT+Pbo group (+0.5% vs. -1.1%; respectively; P&lt;0.01). Knee extension and flexion strength assessed by isokinetic dynamometry increased similarly in the LT+Test group and LT+Pbo group (increase of 17 and 25% vs. 18 and 27%, respectively; P=0.89 to 0.99). Both hematocrit and PSA increased more in the LT+Test group than in the LT+Pbo group (increases of 5% vs. 1% and 45% vs. 0.1%, respectively while HDLc increased less (increase of 0.5% vs. 13%, respectively) (P&lt;0.001 to 0.01 for all comparisons). Total testosterone levels measured by LC-MS increased more in the LT+Test group than in the LT+Pbo group (125% increase [from 222 ng/dl to 546 ng/dl] vs. 19% increase [from 247 ng/dl to 335 ng/dl], respectively; P&lt;0.001).
Conclusions
In older men with hypogonadism and obesity associated with frailty, testosterone replacement therapy significantly augments the increase in endurance capacity in response to lifestyle intervention with diet and regular exercise and helps to preserve muscle and bone mass during weight loss. However, testosterone replacement therapy does not lead to greater amelioration of frailty than in response to intensive lifestyle intervention alone in this population.